NEW YORK, Oct. 12 - Protedyne, which develops automated technology for genomic-based drug discovery, has closed $12 million in a Series B round of private financing, the company said on Friday.

The Sprout Group, a venture capital affiliate of Credit Suisse First Boston, led the institutional placement, according to a statement. Meridian Venture Partners, Long River Ventures, and Boston Community Venture Funds participated in the round, Protedyne said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.